Recursion Pharmaceuticals, Inc.
RXRXDrugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
2
Next Catalyst
Jan 2027
Market Overview
Stock performance and key metrics
3 upcoming, 1 past
RXRX Earnings Report
EPS Est: $-0.23 | FQ end 2026-06 | Call: 2026-08-05 15:00:00
2 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How RXRX's past catalysts played out
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Recursion Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in Recursion Pharmaceuticals, Inc.'s (RXRX) pipeline across Phase 2. Its lead program is GTAEXS617 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Recursion Pharmaceuticals, Inc.'s next FDA catalyst?→
Recursion Pharmaceuticals, Inc.'s (RXRX) next tracked catalyst is a Phase 2 expected July 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track RXRX biotech catalysts?→
Add RXRX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Recursion Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.